Supriya Lifescience · NSE: SUPRIYA · BSE: 543434
Q1 FY26 results · Apr–Jun 2025
Supriya Lifescience reported revenue from operations of ₹145.07 crore (down 9.7% from Q1 FY25) and net profit of ₹34.79 crore (down 22.1% from Q1 FY25) for Q1 FY26 (Apr–Jun 2025), on a standalone basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 145.07 | 160.63 | −9.7% | 184.11 | −21.2% |
| Other income | 2.67 | 2.22 | +20.2% | 2.98 | −10.1% |
| Total income | 147.75 | 162.85 | −9.3% | 187.08 | −21.0% |
| Profit before tax | 47.41 | 59.77 | −20.7% | 64.06 | −26.0% |
| Net profit for the period | 34.79 | 44.64 | −22.1% | 50.38 | −30.9% |
| EPS, basic (₹) | 4.32 | 5.54 | −22.0% | 6.29 | −31.3% |
| Net margin (%) | 24.0 | 27.8 | 27.4 |
Standalone
- Filed with BSE
- 10 Sep 2025, 08:59 IST
- Board meeting
- 13 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE